MYC in cancer: from undruggable target to clinical trials
MYC is among the most infamous oncogenes in cancer. A notable feature that distinguishes it from other common oncogenes is that its deregula…
Tag: Cancer therapy
Treatment advances across the cervical cancer spectrum
Cervical cancer is preventable with screening and vaccination approaches; however, access to these preventative measures is limited both nationally…
PDX models for functional precision oncology and discovery science
Precision oncology relies on detailed molecular analysis of how diverse tumours respond to various therapies, with the aim to optimize treatment ou…
Tumour hypoxia in driving genomic instability and tumour evolution
Intratumour hypoxia is a feature of all heterogenous solid tumours. Increased levels or subregions of tumour hypoxia are associated with an adverse…
ALK in cancer: from function to therapeutic targeting
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that acts as an oncogenic driver in solid and haematological malignancies in b…